Phlexglobal launches eTMF Consulting Group
Phlexglobal has announced the launch of a specialist consulting group along with the appointment of a head of division.
The new eTMF Consulting Group, led by Jane Clarke who joins Phlexglobal from Wyeth, will provide the expertise for companies in all aspects of records management, with a specific focus on TMFs, electronic TMFs (eTMFs) and the migration from paper to electronic.
Phlexglobal has has focused on the support and development of eTMFs for the past eight years. During this time the company has gained experience, leading to the launch of the eTMF Consulting Group.
In addition to running the new Group, Jane will also be responsible for enhancing the functionality of Phlexglobal’s bespoke eTMF solution – PhlexEview – drawing on customer requirements and Phlexglobal’s vision for the future of eTMFs.
During her time at Wyeth, Jane gained experience in the development, integration and support of a variety of clinical research systems - CTMS, EDC, ePRO, eTMF and IVR -through the creation of a dedicated division. Jane also successfully implemented EDC resulting in a 90 per cent take-up in 11 months and the transition from a custom-built to a commercial EDC solution. Jane is a keynote speaker at the 9th Annual Partnerships in Clinical Trials Conference in Vienna in November 2010.
For further information on Phlexglobal’s eTMF solutions, visit the website at www.phlexglobal.com .
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
